Current evidence and future perspectives on anti-platelet and statin pharmacotherapy for patients with symptomatic peripheral arterial disease

Current Vascular Pharmacology

Volumn 15, Issue 5, 2017, Pages 430-445

  Kitrou, Panagiotis ^a   Katsanos, Konstantinos ^a,c   Karnabatidis, Dimitris ^a   Reppas, Lazaros ^b   Brountzos, Elias ^b   Spiliopoulos, Stavros ^b  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiplatelet therapy; Aspirin; Cilostazol; Clopidogrel; Peripheral arterial disease; Statins; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PICOTAMIDE; PLACEBO; TICAGRELOR; TICLOPIDINE; VORAPAXAR; FIBRINOLYTIC AGENT;

ATHEROMA; BLEEDING; CARDIOVASCULAR DISEASE; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REMISSION; REVASCULARIZATION; REVIEW; THROMBOCYTE; COMBINATION DRUG THERAPY; DRUG DESIGN; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME FACTOR;

DRUG DESIGN; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 85041352209     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161115666170504124911     Document Type: Review

References (117)

1. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013; 382(9901): 1329-40.
2. Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008; 52(21): 1736-42.
3. Makowsky MJ, McAlister FA, et al. Lower extremity peripheral arterial disease in individuals with coronary artery disease:Prognostic importance, care gaps, and impact of therapy. Am Heart J 2008; 155(2): 348-55.
4. Adam DJ, Bradbury AW. TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg 2007; 33(1): 1-2.
5. Spiliopoulos S, Kitrou P, Katsanos K, Karnabatidis D. Current Phase II drugs under investigation for the treatment of limb ischemia. Expert Opin Investig Drugs 2015; 24(11): 1447-58. 6.
6. Stalenhoef AF. The benefit of statins in non-cardiac vascular surgery patients. J Vasc Surg 2009; 49(1): 260-5.
7. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ 2014; 349: 3743.
8. Katsanos K, Spiliopoulos S, Saha P, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: A systematic review and network metaanalysis. PLoS One 2015; 10(8): 0135692.
9. Livingston A. Mechanism of action of nonsteroidal antiinflammatory drugs. Vet Clin North Am Small Anim Pract 2000; 30(4): 773-81, vi.
10. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000; 321(7270): 1183-7.
11. Minar E, Ahmadi A, Koppensteiner R, Maca T, Stumpflen A, Ugurluoglu A, et al. Comparison of effects of high-dose and lowdose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995; 91(8): 2167-73.
12. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Vasc Med 2011; 16(6): 452-76.
13. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: A meta-analysis of randomized trials. JAMA 2009; 301(18): 1909-19.
14. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; 11: 001272.
15. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial:Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337: 1840.
16. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA 2010; 303(9): 841-8.
17. Braun OO, Jagroop A, Wang L, Mikhailidis DP, Burnstock G, Erlinge D. Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study. Platelets 2005; 16(5): 261-7.
18. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003; 25(1): 16-22.
19. Tsakiris DA, Tschopl M, Wolf F, Labs KH, Jager KA, Marbet GA. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul Fibrinolysis 2000; 11(2): 165-73.
20. Mohan IV, Mikhailidis DP, Stansby GP. Platelet activation in bypass surgery for critical limb ischemia. Vasc Endovascular Surg 2007; 41(4): 322-9.
21. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47(1): 27-33.
22. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78(3): 1003-7.
23. Madsen EH, Gehr NR, Johannesen NL, Schmidt EB, Kristensen SR. Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets 2011; 22(7): 537-46.
24. Coma-Canella I, Velasc A. Variability in individual responsiveness to aspirin: Clinical implications and treatment. Cardiovasc Hematol Disord Drug Targets 2007; 7(4): 274-87.
25. Karnabatidis D, Spiliopoulos S, Pastromas G, et al. Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing. Cardiovasc Intervent Radiol 2014; 37(3): 631-8.
26. Pasala T, Hoo JS, Lockhart MK, et al. Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease. Tex Heart Inst J 2016; 43(6): 482-7.
27. Armstrong EJ, Anderson DR, Yeo KK, et al. Association of dualantiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 2015; 62(1): 157-65.
28. Modesti PA, Colella A, Abbate R, Gensini G, Neri Serneri G. Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol 1989; 169(1): 85-93.
29. Gresele P, Deckmyn H, Arnout J, Nenci GG, Vermylen J. Characterization of N, N’-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb Haemost 1989; 61(3): 479-84.
30. Coto V, Cocozza M, Oliviero U, et al. Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 1989; 40(10): 880-5.
31. Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993; 87(5): 1563-9.
32. Neirotti M, Molaschi M, Ponzetto M, et al. Hemodynamic, hemorheologic, and hemocoagulative changes after treatment with picotamide in patients affected by peripheral arterial disease (PAD) of the lower limbs. Angiology 1994; 45(2): 137-41.
33. Neri Serneri GG, Coccheri S, Marubini E, Violi F. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25(20): 1845-52.
34. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 12(7): 443-7.
35. Klonaris C, Patelis N, Drebes A, Matheiken S, Liakakos T. Antiplatelet treatment in peripheral arterial disease: The role of novel antiplatelet agents. Curr Pharm Des 2016; 22(29): 4610-6.
36. Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4(5): 252-61.
37. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-39.
38. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127(13): 1425-43.
39. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: The PRECLOP study: Clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 2013; 61(24): 2428-34.
40. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005; 45(8): 1157-64.
41. Pastromas G, Spiliopoulos S, Katsanos K, et al. Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol 2013; 36(6): 1493-9.
42. Spiliopoulos S, Pastromas G, Diamantopoulos A, Katsanos K. Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. Expert Opin Pharmacother 2014; 15(15): 2205-17.
43. Mazur P, Frolow M, Nizankowski R, Sadowski J, Undas A. Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Platelets 2013; 24(2): 151-5.
44. Wand S, Baro D, Baecker C, et al. Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. Clin Lab 2014; 60(10): 1601-7.
45. Leunissen TC, Peeters Weem SM, et al. High on-treatment platelet reactivity in peripheral arterial disease: A pilot study to find the optimal test and cut off values. Eur J Vasc Endovasc Surg 2016; 52(2): 198-204.
46. Guo B, Tan Q, Guo D, Shi Z, Zhang C, Guo W. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease. J Vasc Surg 2014; 60(4): 993-1001.
47. Gary T, Pruller F, Raggam R, et al. High residual collagen-induced platelet reactivity predicts development of restenosis in the superficial femoral artery after percutaneous transluminal angioplasty in claudicant patients. Cardiovasc Intervent Radiol 2016; 39(2): 190-4.
48. Leunissen TC, Peeters Weem SM, et al. High on-treatment platelet reactivity in peripheral arterial disease: A pilot study to find the optimal test and cut off values. Eur J Vasc Endovasc Surg 2016; 52(2): 198-204.
49. Bernlochner I, Jaitner J, Fries V, et al. High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease. Vasa 2016; 45(2): 155-61.
50. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost 2014; 111(3): 474-82.
51. Wysowksi DK, Bacsanyi J. Blood dycrasias and hematologic reactions in ticlopidine users. JAMA 1996; 276(12): 952.
52. Fagher B. Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis: A double-blind study. Angiology 1994; 45(9): 777-88.
53. Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol 2011; 72(4): 647-57.
54. Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish ticlopidine multicentre study (STIMS). Eur J Vasc Endovasc Surg 1995; 10(1): 69-76.
55. Hiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. N Engl J Med 2017; 376(1): 32-40.
56. Jones WS, Baumgartner I, Hiatt WR, et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation 2017; 135(3): 241-50.
57. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: Results from TRA20P-TIMI 50. Circulation 2013; 127(14): 1522-9.
58. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4 (Suppl 2): 14-9.
59. Rogers KC, Oliphant CS, Finks SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs 2015; 75(4): 377-95.
60. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014; 10: 003748.
61. Lim PS, Jeng Y, Wu MY, Pai MA, Wu TK, Chen CH. Role of cilostazol therapy in hemodialysis patients with asymptomatic peripheral arterial disease: A retrospective cohort study. Biomed Res Int 2016; 2016: 8236903.
62. Perez P, Esteban C, Sauquillo JC, et al. Cilostazol and outcome in outpatients with peripheral artery disease. Thromb Res 2014; 134(2): 331-5.
63. de Donato G, Setacci F, Galzerano G, Mele M, Ruzzi U, Setacci C. The use of cilostazol in patients with peripheral arterial disease:results of a national physician survey. J Cardiovasc Surg (Torino) 2016; 57(3): 457-65.
64. Sanada F, Kanbara Y, Taniyama Y, et al. Induction of angiogenesis by a type iii phosphodiesterase inhibitor, cilostazol, through activation of peroxisome proliferator-activated receptor-gamma and camp pathways in vascular cells. Arterioscler Thromb Vasc Biol 2016; 36(3): 545-52.
65. Chao TH, Tseng SY, Chen IC, et al. Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. Int J Cardiol 2014; 172(2): 371-4.
66. Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP. Cilostazol and atherogenic dyslipidemia: A clinically relevant effect? Expert Opin Pharmacother 2011; 12(4): 647-55.
67. Nanto K, Iida O, Takahara M, et al. Effect of cilostazol following endovascular intervention for peripheral artery disease. Angiology 2015; 66(8): 774-8.
68. Lee WH, Chu CY, Hsu PC, et al. Cilostazol for primary prevention of stroke in peripheral artery disease: A population-based longitudinal study in Taiwan. Thromb Res 2013; 132(2): 190-5.
69. Lee WH, Chu CY, Hsu PC, et al. Comparison of antiplatelet and antithrombotic therapy for secondary prevention of ischemic stroke in patients with peripheral artery disease: Population-based followup study in Taiwan. Circ J 2013; 77(4): 1046-52.
70. Belch JJ, Dormandy J, Biasi GM, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52(4): 825-33.
71. Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: A randomised and double-blinded clinical trial. Eur Radiol 2012; 22(9): 1998-2006.
72. Mukherjee D, Topol EJ, Moliterno DJ, et al. Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart 2006; 92(1): 49-51.
73. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008; 47(2): 330-6.
74. Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009; 53(1): 48-53.
75. Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation 2013; 127(23): 2307-15.
76. Soga Y, Iida O, Hirano K, et al. Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia. J Vasc Surg 2011; 54(6): 1659-67.
77. Iida O, Nanto S, Uematsu M, Morozumi T, Kitakaze M, Nagata S. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008; 48(1): 144-9.
78. Zen K, Takahara M, Iida O, et al. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. J Vasc Surg 2017; 65(3): 720-5.
79. Iftikhar O, Oliveros K, Tafur AJ, Casanegra AI. Prevention of femoropopliteal in-stent restenosis with cilostazol: A metaanalysis. Angiology 2016; 67(6): 549-55.
80. Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vasc Endovasc Surg 2012; 44(6): 577-81.
81. Neel JD, Kruse RL, Dombrovskiy VY, Vogel TR. Cilostazol and freedom from amputation after lower extremity revascularization. J Vasc Surg 2015; 61(4): 960-4.
82. Spiliopoulos S, Katsanos K, Pastromas G, et al. Initial experience with ticagrelor in patients with critical limb ischemia and high onclopidogrel platelet reactivity undergoing complex peripheral endovascular procedures. Cardiovasc Intervent Radiol 2014; 37(6): 1450-7.
83. Paraskevas KI, Giannoukas AD, Mikhailidis DP. Statins and infrainguinal vascular bypass procedures. Curr Vasc Pharmacol 2013; 11(1): 51-7.
84. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipidlowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007; 4: 000123.
85. Lee JH, Ko YG, Shin DH, et al. Attainment of low-density lipoprotein cholesterol goal after endovascular treatment is associated with reduced cardiovascular events in patients with peripheral arterial disease. J Vasc Surg 2016; 63(3): 756-63.
86. Stoekenbroek RM, Boekholdt SM, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart 2015; 101(5): 356-62.
87. Tomoi Y, Soga Y, Iida O, et al. Efficacy of statin treatment after endovascular therapy for isolated below-the-knee disease in patients with critical limb ischemia. Cardiovasc Interv Ther 2013; 28(4): 374-82.
88. Suckow BD, Kraiss LW, Schanzer A, et al. Statin therapy after infrainguinal bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg 2015; 61(1): 126-33.
89. Westin GG, Armstrong EJ, Bang H, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014; 63(7): 682-90.
90. Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014; 3(2): e000697.
91. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355(6): 549-59.
92. Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American heart association and American college of cardiology foundation endorsed by the world heart federation and the preventive cardiovascular nurses association. J Am Coll Cardiol 2011; 58(23): 2432-46.
93. Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108(12): 1481-6.
94. Vogel TR, Dombrovskiy VY, Galinanes EL, Kruse RL. Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv 2013; 6(6): 694-700.
95. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363(9411): 757-67.
96. Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and longterm adverse limb outcomes in patients with peripheral artery disease: insights from the reach registry. Eur Heart J 2014; 35(41): 2864-72.
97. Antoniou GA, Fisher RK, Georgiadis GS, Antoniou SA, Torella F. Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis. Vascul Pharmacol 2014; 63(2): 79-87.
98. Harris SK, Roos MG, Landry GJ. Statin use in patients with peripheral arterial disease. J Vasc Surg 2016; 64(6): 1881-8.
99. Natsuaki M, Furukawa Y, Morimoto T, et al. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. Circ J 2012; 76(6): 1369-79.
100. Lee SW, Hau WK, Kong SL, et al. Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: The venus study. Circ J 2012; 76(11): 2662-72.
101. Pelliccia F, Rosano G, Marazzi G, et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy. Circ J 2014; 78(3): 679-84.
102. Yun KH, Jeong MH, Oh S, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009; 137(3): 246-51.
103. Kim JS, Kim J, Choi D, et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in STsegment elevation myocardial infarction: The statin stemi trial. JACC Cardiovasc Interv 2010; 3(3): 332-9.
104. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116(9): 1509-26.
105. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries:The task force on the diagnosis and treatment of peripheral artery diseases of the european society of cardiology (ECS). Eur Heart J 2011; 32(22): 2851-906.
106. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385(9985): 2371-82.
107. Ullery BW, Tran K, Itoga N, Casey K, Dalman RL, Lee JT. Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease. J Vasc Surg 2015; 61(6): 1479-88.
108. Eldor R, Raz I. American diabetes association indications for statins in diabetes: Is there evidence? Diabetes Care 2009; 32(Suppl 2): 384-91.
109. Hira RS, Cowart JB, Akeroyd JM, et al. Risk factor optimization and guideline-directed medical therapy in us veterans with peripheral arterial and ischemic cerebrovascular disease compared to veterans with coronary heart disease. Am J Cardiol 2016; 118(8): 1144-9.
110. Chrysant SG. New onset diabetes mellitus induced by statins:Current evidence. Postgrad Med 2017; 129(4): 430-35.
111. Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World J Diabetes 2015; 6(2): 352-7.
112. Brunner G, Yang EY, Kumar A, et al. The effect of lipid modification on peripheral artery disease after endovascular intervention trial (ELIMIT). Atherosclerosis 2013; 231(2): 371-7.
113. Kono Y, Fukuda S, Shimada K, et al. Very rapid effect of pitavastatin on microvascular function in comparison to rosuvastatin: reactive hyperemia peripheral arterial tonometric study. Drug Des Devel Ther 2013; 7: 369-74.
114. Simic I, Reiner Z. Adverse effects of statins - myths and reality. Curr Pharm Des 2015; 21(9): 1220-6.
115. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007; 50(5): 409-18.
116. Lowe RN, Marrs JC, Saseen JJ. Patterns of serum laboratory monitoring for safety and efficacy in patients on chronic statin therapy. Ther Adv Drug Saf 2013; 4(1): 9-17.
117. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: Meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012; 7(1): e29849.